The clinical usage of one of the main checkpoint inhibitors, UCN-01, was limited due to its destruction by plasma proteins in vivo, therefore new small molecule inhibitors of Chk1 or Chk2 are needed that avoid this issue so as to test their therapeutic potential for sensitizing p53-deficient cancer cells [41]. This evidence concerns the gene CHEK2 and cancer.